This document provides an overview of audits and inspections for quality management in life sciences. It defines audits and inspections, describes types of each, and outlines focus areas. Key aspects of audits covered include classification of findings, root cause analysis, corrective action processes, audit tools, and dos and don'ts. Good documentation practices, risk management, and escalation management processes are also summarized. The purpose is to educate on quality policy, audits, inspections, and related quality management topics in life sciences.
Integrating Clinical Operations and Clinical Data Management Through EDCwww.datatrak.com
When electronic data capture was first introduced there was a great deal of discussion surrounding how the technology would alter the roles of those in clinical operations and clinical data management. Through the review of a case study, we will explore how EDC is used as a tool to more tightly integrate clinical operational staffs with those in clinical data management resulting in a more streamlined process from study initiation to database lock.
Visit:www.acriindia.com
ACRI is a leading Clinical data management training Institute in Bangalore India.
ACRI creates a value add for every degree. Our PGDCRCDM course is approved by the Mysore University. Graduates and Post Graduates and even PhDs have trained with us and got enviable positions in the Clinical Research Industry. ACRI supplements University training with Industry based training, coupled with hands-on internships and projects based on real case studies. The ACRI brand gives the individual the confidence and expertise to join the ever-growing workforce both in the country and abroad.
Electronic Data Capture & Remote Data CaptureCRB Tech
CRB Tech is one of the best leading Software Development Company in Pune. We are offering Software Development Services as well as IT Training including Java, Dot Net, SEO and Clinical Research training in pune.
An brief introduction to the clinical data management process is described in this slides. These slides provides you the information regarding the data evaluation in the clinical trials , edit checks and data review finally data locking,then the data is submitted to the concerned regulatory body.
Integrating Clinical Operations and Clinical Data Management Through EDCwww.datatrak.com
When electronic data capture was first introduced there was a great deal of discussion surrounding how the technology would alter the roles of those in clinical operations and clinical data management. Through the review of a case study, we will explore how EDC is used as a tool to more tightly integrate clinical operational staffs with those in clinical data management resulting in a more streamlined process from study initiation to database lock.
Visit:www.acriindia.com
ACRI is a leading Clinical data management training Institute in Bangalore India.
ACRI creates a value add for every degree. Our PGDCRCDM course is approved by the Mysore University. Graduates and Post Graduates and even PhDs have trained with us and got enviable positions in the Clinical Research Industry. ACRI supplements University training with Industry based training, coupled with hands-on internships and projects based on real case studies. The ACRI brand gives the individual the confidence and expertise to join the ever-growing workforce both in the country and abroad.
Electronic Data Capture & Remote Data CaptureCRB Tech
CRB Tech is one of the best leading Software Development Company in Pune. We are offering Software Development Services as well as IT Training including Java, Dot Net, SEO and Clinical Research training in pune.
An brief introduction to the clinical data management process is described in this slides. These slides provides you the information regarding the data evaluation in the clinical trials , edit checks and data review finally data locking,then the data is submitted to the concerned regulatory body.
This Presentation is about why CRO/Vendor oversight should support sponsor regulatory requirements and cost containment.
Topics covered:
1.Importance of CRO/Vendor oversight in clinical trial management.
2. Identify the ways to integrate a risk-based approaches to CRO/Vendor oversight.
3. Developing a CRO/Vendor oversight plan with appropriate KPIs/metrics to be measured.
4. Use of tools and technology for accurate and timely reporting.
Have full fleged clinical trial data management systems which bring them a good amount of business and revenue.
CDM is a fundamental process which controls data accuracy of each trial besides helping the timelessness to be achieved.
It helps in linking clinical research co-ordinator = who monitor all the sites & collects the data.
it Links with biostatisticians = who analyze, interpret and report data in clinically meaningful way.
Monitoring plan and basic monitoring visits: everything that a cra needs to knowTrialJoin
A monitor in a clinical trial is also called a CRA - clinical research associate. This person is a professional who’s responsible for monitoring the clinical trial and making sure that everything is according to rules, regulations, and good clinical practice.
Whether you already are a CRA or you’re trying to become one, the most important thing you should be aware of is the monitoring plan. You, as a CRA or a future CRA, should know what a monitoring plan is, what it serves for, and what it consists of. The second most important information for you are the monitoring visits. Below, we’ll explain all the components of a monitoring plan, as well as which are the most basic and important monitoring visits.
TSDP tells about the essential documents that are required for the #conduct of a clinical trial. For #regulatory medical writing training, contact hello@turacoz.in.
Clinical Data Management (CDM) is a critical component of clinical research that involves the collection, cleaning, validation, and management of clinical trial data to ensure its accuracy, integrity, and compliance with regulatory requirements. The workflow of CDM typically consists of several key stages, each with specific activities and processes. Here is an overview of the typical workflow of CDM:
Study Startup:
Protocol Review: CDM teams begin by reviewing the clinical trial protocol to understand the study's objectives, endpoints, data collection requirements, and timelines.
Database Design: Based on the protocol, the team designs a data capture system or electronic data capture (EDC) system. This includes creating data entry forms, defining data validation checks, and setting up data dictionaries.
Data Collection:
Case Report Form (CRF) Design: CDM professionals design electronic or paper CRFs to collect data during the trial. CRFs capture specific data points required by the protocol.
Data Entry: Data is entered into the CRFs, either electronically by site personnel or through paper CRFs.
Data Validation: CDM teams implement validation checks to ensure data quality and consistency. Data validation checks may include range checks, consistency checks, and logic checks.
Query Management: Queries are generated when data discrepancies or inconsistencies are identified. CDM teams send queries to investigational sites for resolution.
Data Cleaning and Quality Control:
Data Cleaning: Data are cleaned to resolve discrepancies, discrepancies, and inconsistencies. This involves querying data discrepancies with clinical trial sites.
Data Review: CDM teams review data to ensure completeness and accuracy, and any outstanding queries are resolved.
Quality Control: Quality control processes are applied to verify the integrity and accuracy of data.
Database Lock:
Once the data are cleaned, reviewed, and validated, the database is locked, indicating that no further changes can be made to the data. Database lock is a critical step before data analysis begins.
Data Export and Analysis:
Data is exported from the database and provided to biostatisticians and researchers for statistical analysis. This analysis is conducted to determine the study's outcomes, efficacy, and safety profile.
Data listings, summaries, and tables are generated for regulatory submissions, reports, and publications.
Final Study Reporting:
After data analysis, CDM teams contribute to the preparation of final study reports, which provide a comprehensive overview of the trial's results, data quality, and regulatory compliance.
Archiving and Documentation:
Clinical trial data, documentation, and databases are archived to ensure their long-term availability for regulatory audits and future reference.
Regulatory Submission: CDM teams provide support for regulatory submissions.
In the course of any clinical trial, there are risks associated with specific activities and tasks. This webinar will highlight some of these key risk areas and provide guidance on combining technology with best practices to help mitigate risks.
In any work or process documents that are needed before initiation, Between or generally the end of the process just like in a clinical trial those “Documents which permit evaluation of the conduct of a trial and the quality of the data produced. It is given in the 8th section of the ICH-GCP.
ARGUS Query Process Overview_Katalyst HLSKatalyst HLS
Introduction to ARGUS Query Process Overview in Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Will I see you in Philadelphia next week? In case you don’t already know, I’ve been invited to speak at CBI’s Risk-Based Trial Management and Monitoring Conference.
I’m going to be sharing real world, pragmatic guidance that you can implement immediately to effectively influence your clinical trial performance.
My presentation, Practical Usage of KRIs and QTLs in Clinical Trials, will take place next Thursday, November 14th at 9:45am. I’m going to share with you:
• How to identify and close the gaps between risks and KRIs
• What the difference is between KRIs and QTLs, and how to use them effectively
• Useful examples of Centralized Monitoring findings from open data
• How to detect, combat and prevent fraud and sloppiness at an early stage
• How AI and ML advance risk-based approaches
So I can’t wait to see you at this informative and fun-filled industry expert forum,
– Artem Andrianov, CEO Cyntegrity
This Presentation is about why CRO/Vendor oversight should support sponsor regulatory requirements and cost containment.
Topics covered:
1.Importance of CRO/Vendor oversight in clinical trial management.
2. Identify the ways to integrate a risk-based approaches to CRO/Vendor oversight.
3. Developing a CRO/Vendor oversight plan with appropriate KPIs/metrics to be measured.
4. Use of tools and technology for accurate and timely reporting.
Have full fleged clinical trial data management systems which bring them a good amount of business and revenue.
CDM is a fundamental process which controls data accuracy of each trial besides helping the timelessness to be achieved.
It helps in linking clinical research co-ordinator = who monitor all the sites & collects the data.
it Links with biostatisticians = who analyze, interpret and report data in clinically meaningful way.
Monitoring plan and basic monitoring visits: everything that a cra needs to knowTrialJoin
A monitor in a clinical trial is also called a CRA - clinical research associate. This person is a professional who’s responsible for monitoring the clinical trial and making sure that everything is according to rules, regulations, and good clinical practice.
Whether you already are a CRA or you’re trying to become one, the most important thing you should be aware of is the monitoring plan. You, as a CRA or a future CRA, should know what a monitoring plan is, what it serves for, and what it consists of. The second most important information for you are the monitoring visits. Below, we’ll explain all the components of a monitoring plan, as well as which are the most basic and important monitoring visits.
TSDP tells about the essential documents that are required for the #conduct of a clinical trial. For #regulatory medical writing training, contact hello@turacoz.in.
Clinical Data Management (CDM) is a critical component of clinical research that involves the collection, cleaning, validation, and management of clinical trial data to ensure its accuracy, integrity, and compliance with regulatory requirements. The workflow of CDM typically consists of several key stages, each with specific activities and processes. Here is an overview of the typical workflow of CDM:
Study Startup:
Protocol Review: CDM teams begin by reviewing the clinical trial protocol to understand the study's objectives, endpoints, data collection requirements, and timelines.
Database Design: Based on the protocol, the team designs a data capture system or electronic data capture (EDC) system. This includes creating data entry forms, defining data validation checks, and setting up data dictionaries.
Data Collection:
Case Report Form (CRF) Design: CDM professionals design electronic or paper CRFs to collect data during the trial. CRFs capture specific data points required by the protocol.
Data Entry: Data is entered into the CRFs, either electronically by site personnel or through paper CRFs.
Data Validation: CDM teams implement validation checks to ensure data quality and consistency. Data validation checks may include range checks, consistency checks, and logic checks.
Query Management: Queries are generated when data discrepancies or inconsistencies are identified. CDM teams send queries to investigational sites for resolution.
Data Cleaning and Quality Control:
Data Cleaning: Data are cleaned to resolve discrepancies, discrepancies, and inconsistencies. This involves querying data discrepancies with clinical trial sites.
Data Review: CDM teams review data to ensure completeness and accuracy, and any outstanding queries are resolved.
Quality Control: Quality control processes are applied to verify the integrity and accuracy of data.
Database Lock:
Once the data are cleaned, reviewed, and validated, the database is locked, indicating that no further changes can be made to the data. Database lock is a critical step before data analysis begins.
Data Export and Analysis:
Data is exported from the database and provided to biostatisticians and researchers for statistical analysis. This analysis is conducted to determine the study's outcomes, efficacy, and safety profile.
Data listings, summaries, and tables are generated for regulatory submissions, reports, and publications.
Final Study Reporting:
After data analysis, CDM teams contribute to the preparation of final study reports, which provide a comprehensive overview of the trial's results, data quality, and regulatory compliance.
Archiving and Documentation:
Clinical trial data, documentation, and databases are archived to ensure their long-term availability for regulatory audits and future reference.
Regulatory Submission: CDM teams provide support for regulatory submissions.
In the course of any clinical trial, there are risks associated with specific activities and tasks. This webinar will highlight some of these key risk areas and provide guidance on combining technology with best practices to help mitigate risks.
In any work or process documents that are needed before initiation, Between or generally the end of the process just like in a clinical trial those “Documents which permit evaluation of the conduct of a trial and the quality of the data produced. It is given in the 8th section of the ICH-GCP.
ARGUS Query Process Overview_Katalyst HLSKatalyst HLS
Introduction to ARGUS Query Process Overview in Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Will I see you in Philadelphia next week? In case you don’t already know, I’ve been invited to speak at CBI’s Risk-Based Trial Management and Monitoring Conference.
I’m going to be sharing real world, pragmatic guidance that you can implement immediately to effectively influence your clinical trial performance.
My presentation, Practical Usage of KRIs and QTLs in Clinical Trials, will take place next Thursday, November 14th at 9:45am. I’m going to share with you:
• How to identify and close the gaps between risks and KRIs
• What the difference is between KRIs and QTLs, and how to use them effectively
• Useful examples of Centralized Monitoring findings from open data
• How to detect, combat and prevent fraud and sloppiness at an early stage
• How AI and ML advance risk-based approaches
So I can’t wait to see you at this informative and fun-filled industry expert forum,
– Artem Andrianov, CEO Cyntegrity
Internal Audit Best Practices for Safety, Environment, and Quality AuditsNimonik
Nimonik has seen a wide variety of internal Health, Safety, Environmental and Quality (HSEQ) audit programs. They seem to come in all shapes and sizes! Each company tends to focus on different risks and controls.
Whether your organization conforms to ISO 19011 or another internal audit standard, re-focusing your internal audit program on your risks, controls, and operational reality is a key driver for operational excellence.
On March 14th, John Wolfe shared insights from over 20 years as a hands-on HSE Director and as the Sr. Director of Operations Integrity Audit for a global Oil & Gas company. John outlined the attributes of an outstanding Internal audit program. He showed you how you can build out a program tailored to your operations and add tremendous value to your business.
CRO/Vendor oversight should support sponsor regulatory requirements and cost containment.Quality Management in clinical operations are Centralized Monitoring, Study Quality Metrics and CRO Oversight.
Presentation delivered by Lori A. Tierney, BSN, Director, Site Management Operations, Allergan, Inc. at the marcus evans Evolution Summit Fall 2019 in San Diego CA.
Presented for ASQ India on 3/22/2016 7PM - 8PM IST (6.30 AM -7.30AM PST). Govind will briefly discuss key changes, new requirements and a high level transition plan. The new standard is more aligned with business than ever. However this new standard also bring challenges for auditing. As a QMS manager, auditor or even a practitioner you will be expected to apply this management system standard at work.
Verification looks at the HACCP system to ensure that it is set up in the correct way and that the business is following the HACCP plan, in particular ensuring that the CCPs are under control. Very simply, verification involves performing tests, checking that procedures are being adhered to and reviewing the HACCP system to ensure that the food being produced is safe.
Main points covered:
• Verification activities for pre-requisites programs
• Verification of HACCP Plan
• Method of verification
• Analysis of verification results
Presenter:
Sheryl Anderson is Managing Director of Quality Systems Solutions & Initiatives (QSSI), which is a consultancy organization that offers training, implementation and audit services in ISO 22000, ISO 9001 and HACCP. She is an ISO 9001 Lead Auditor and a certified trainer for HACCP, ISO 9001, ISO 22000 and other quality improvement courses.
Link of the recorded session published on YouTube: http://www.slideshare.net/PECBCERTIFICATION/verification-planning-of-food-safety-system
Root cause Analysis (RCA) & Corrective and Preventive action (CAPA) in MRCT d...Bhaswat Chakraborty
This presentation describes Identification & differentiation of Protocol deviation & violation; Different methods of RCA & best suitable method for Multiregional Clinical Trial; CAPA management and CAPA application to other trial sites/CRO/SMO/ Country that is involved in same trial (Strategic Management and application of CAPA in MRCT)
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
2. 2
What we will learn today?
1. Quality Policy
2. Audits & Inspections
3. Inspection Readiness
4. Internal Audits:
5. Classification of Audit Findings
6. RCA & CAPA
7. Audit tool
8. Audit Do’s and Don’ts
9. Introduction to Good Documentation Practice (GDP)
10. Tips for GDP
11. Risk Management
12. Escalation Management
3/27/2017Katalyst HealthCares & Life Sciences
3. 3
Introduction: Quality Management System (QMS)
Quality Policy Manual
Frameworks and Generic
Procedures (Project
Management)
Life Sciences (IT + BPS)
SOP/ SWP/ SWI (Guidelines)
Client Specific Procedures +
Templates
Client Specific Instructions
(Usage of tools and
templates)
Governed by ISO 9001:2008,
eSCM (eSourcing Capability
Model), CMMi and Regulatory
norms.
In addition to above, these
are governed by Client
specific SOPs/ SWPs/
SWIs.
Process
Space
Project
Repository
Storing location Type of document Governance
3/27/2017Katalyst HealthCares & Life Sciences
4. 4
Definitions & Differences
AUDIT INSPECTION
Definition A systematic and independent
examination of trial related activities and
documents to determine whether the
evaluated trial related activities were
conducted, and the data were recorded,
analyzed and accurately reported
according to the protocol, sponsor's
standard operating procedures (SOPs),
Good Clinical Practice (GCP), and the
applicable regulatory requirement(s).
(ICH-GCP E6-R1 - Section# 1.6)
The act by a regulatory authority (ies) of
conducting an official review of documents,
facilities, records, and any other resources
that are deemed by the authority (ies) to be
related to the clinical trial and that may be
located at the site of the trial, at the
sponsor's and/ or contract research
organization’s (CRO’s) facilities, or at other
establishments deemed appropriate by the
regulatory authority (ies). (ICH-GCP E6-R1
– Section# 1.29)
Purpose To check on compliance, process
improvement, data credibility, preparation
for regulatory inspection.
In addition to it - Inspection is the basis of
granting marketing authorization approval.
3/27/2017Katalyst HealthCares & Life Sciences
5. 5
Types of Audit/ Inspection
▪ Types of Audit:
▪ Internal audit
▪ Customer/ Client audits/ Third Party Audit
▪ ISO 9001:2008 Surveillance audits, etc.
▪ Types of Inspection:
▪ PAIs (Pre-Approval Inspections)
▪ For Cause Inspections
▪ Routine Inspections
▪ Pre-Inspection visits (by some Indian regulatory agencies)
3/27/2017Katalyst HealthCares & Life Sciences
6. 6
Focus Area for Audit/ Inspections
ProcessPeople
Interview of
resources
Training
records
JD/ RD/ CV BG Checks Resource
Skill
Application
Access
Management
Tool
Validation
Records
Staff
Turnover
Capacity & back
log plan
Access Invoke/
revoke
records
Application
problem
Management
BCP
test records
MSA/SOW
Addendum
SOPs/SWIs
Management
Quality
Control
Quality
Assurance
Deviation
Management
Training
Management
SLA/ KPI
Monitoring
Change
Management
Risk
Management
CAPA
Management
Tool
Validation
Governance
Escalation plan
OrganogramBCP & disaster
recovery plan
Data privacy &
security
Customer
communication
Issue & Problem
Management
Inspection
management
Vendor
management
Document management system
Handover
takeover
Archival
process
Regulatory
updates
ICSR Case
Processing
Quality Control
Activities
Lock/ Unlock
activities
Study Set-up
activities
Statistical Related
activities
Study Conduct /
Closeout
Allocation/
Assignment
Medical Writing
Reports/ Narrative
Study
Documentation
Signal
Detection
Regulatory/
Document
Publishing activities
Technology
Aggregate
Reporting
7. Transition (Start Up) Steady State (Engagement Lifecycle) Closure
T3 Audit
T6/ Go- Live Audit
Study Audit
(For CDM)
Closure
Transition
Manager,
Project Manager
•Scope & Solution
Design
•Contract
Assessment
•Governance
•People profile
•As Is Process
Maps
•KT Plan
•Engagement Risks
End of T3 stage of
transition
Transition
Manager,
Project Manager
•Contract
Assessment
•KT assessment
•Quality Plan
•Deployment
Requirements
•Process Map SOP/
SWP/ SWI
•Capacity Planning
& Ramp up etc.
Before Go-Live (T6) of
the project
Study Team
Members
•Specific Work
Instructions,
SOPs, SWPs
• Study specific
documents
•Configuration
Management
•Quality Control
•Trainings
•Study
Deliverables
Go-Live, DBL
Milestone
Project
Manager
•Service
Transfer
•Retention &
Archival
•Lessons
Learnt
•Access
Revoke
•Resource
transfer out (if
applicable)
Once (At the
end of the
project)
Process Audit
Project Manager,
Transition Manager,
Team Manager,
Team Leader
•MSA/ SOW Execution
(Contract Management)
•Capacity Plan
•QMS Adherence (SOP
and Plan adherence)
•Configuration Mgmt
•Training and Quality
•Metric Management
•Change Management
•Issue Mgmt
•BCP & DR
•Risk Mgmt etc.
Based on C1/ C2/ C3
projects and special
requests by BUs
System Audits
Project Manager,
Team Manager,
Team Leader,
Team Members
•Specific Work
Instructions, SOP,
guidelines
• Study specific
documentations
•Configuration
Management
•Quality Control
•Trainings
•Sample case
assessment (In case
of PV engagement)
Annual
For Cause Audit
Project Manager,
Relevant stakeholder
involved
•Consistent dip in
quality/ accuracy
scores
•Major non-
compliance to the
contractual or
regulatory
requirements
•Customer
feedback/concerns
As and when
required
Joint Quality Management Review
• Joint Quality review to ensure process compliance
• Identification of focus area based on Client feedback
• Communicating critical changes and process updates
• Building common forum to discuss process compliance &
risk
Inspection Readiness
• Building mechanism to share information on Inspection
• Validating inspection readiness preparedness
Regulatory Updates
• Building mechanism to track regulatory
updates specific to outsourced scope of
work
• Building mechanism to communicate
regulatory updates
• Governance Plan
• Communication Plan
Frequenc
y
Focus
Auditee
Quality Management Review with Client QA SPOC (Based on mutual agreement)
7
Audits (Life Science)
T3 Audit
3/27/2017Katalyst HealthCares & Life Sciences
8. 8
Classification of Audit Finding
▪ Non Conformance (NC): Audit finding is tagged to NC wherein there is failure
to meet defined requirements and evidence for same is observed during the audit.
The non-conformance in turn can be categorized as either Critical, Major and Minor
based on the severity of the Non Conformance.
• Critical NC
• Major NC
• Minor NC
▪ Suggestions: Recommendation to improve service based on good practices noted
from other engagements, as per auditor’s discretion.
▪ Audit Note: A factual statement that is required to be noted and documented in
the audit report. This is reporting of an event in the project and not a Non
Conformance.
▪ Good Practices: During the audit, if the Auditor identifies any unique practice
which contributes significantly to the objectives, these practices can be termed as
Good practices for the project.
3/27/2017Katalyst HealthCares & Life Sciences
9. 9
RCA & CA-PA
▪ Correction: An action taken to rectify/ fix the issue/non-conformance
▪ Root Cause: A root cause is the reason for a condition or an action at its origin or source. It is
the cause of a causal chain which leads to a Non-conformance..
▪ Root Cause Analysis: The process of determining the root cause from all the possible
causes. It is structured and thorough review of problem designed to identify and verify what is
causing the symptoms.
▪ Corrective Action: Action taken to prevent recurrence of a known nonconformance.
Corrective Action addresses the Root cause of an actual problem.
▪ Preventive Action: Action taken to prevent occurrence of a potential nonconformance.
▪ Risk: The combination of the probability of occurrence of harm and the severity of that harm
(ICH-Q9). The cumulative effect of the chances of uncertain occurrences adversely affecting
project objectives.
3/27/2017Katalyst HealthCares & Life Sciences
10. 10
Risk Management - Multi-Layered Risk Governance
Risky Project
Review (BU Heads)
Risk Identification
Critical Risky
Project Review
(Exec Leadership)
Risk governance will involve various groups of stakeholders including Service Line Leads,
Executive Leadership, Industrialize/ Enable Leads and Risk Management team depending on the
project context and the level of risk review being performed
Risky Project
Review
(BU Heads)
Highly Critical
Project Review
(Senior Leadership)
▪ Risk
identification
▪ Mainspring
logging
▪ Enable
discussion with
BU Heads
▪ Critical risk
projects
identified for
Exec review
▪ Escalation potential
discussion
▪ Need for SLT review
▪ Actions for
addressing
▪ critical challenges
Risk management is a systematic process for the assessment, control, communication and review of risk to the quality
of the medicinal product across the product lifecycle ( ICH Q9)
19 3/27/2017Katalyst HealthCares & Life Sciences
11. 11
Audit Tool
Audit Reporting
• Audit Findings are reported in Audit tool
CAPA Management
• Operations provide CAPA for each individual finding
• Provide relevant evidences within completion timelines
• Document the corrective and/ or preventive in order to
address the root cause
• Verify the evidences for completeness and adequate/
effective CAPA for closure of audit findings
• CAPA effectiveness is monitored for implemented
corrective and preventive action
• Regular reports are published to management on the
Audit Compliance metrics
3/27/2017Katalyst HealthCares & Life Sciences
12. 12
Do’s for Audit/ Inspection
▪ Identify/ Assign facilitator for audit/ inspection
▪ Understand – Purpose/ scope of the audit/ inspection
▪ Ensure compliance to the company policies and regulatory guidelines
▪ Be thorough with all your processes and calibrated amongst the team. Keep
consistency throughout the process explanation
▪ Ensure completeness of all necessary documentation, e.g., training, project related
▪ Keep all the SOPs updated and ensure all the associates are trained on all SOPs
▪ Always lock your PCs and also keep your operations area locked
▪ Keep your password secret from everyone
▪ Wear your valid ID card and use it before entering to any door.
▪ Provide your business card to auditor/ inspector in the start of the meeting.
▪ Project an attitude of confidence and professionalism.
▪ Keep your cell phones either switched off or on silent mode.
▪ Keep all training documentation ready (including ex-employees, in archive)
3/27/2017Katalyst HealthCares & Life Sciences
13. 13
Do’s for Audit/ Inspection
▪ All documents/ artifacts to be stored in the shared drive/ share point.
▪ Keep documented evidence for any deviation. Be aware of what is available
and have proper justifications for what is not available
▪ Document whatever you do- ‘Anything not documented is considered as not done’.
▪ Make and maintain a set of duplicate copies of any documents provided to the Auditor (To
be provided only after authorization from the manager)
▪ Make sure all the necessary documents are in the control room, so that you may produce
the same to the auditor without delay.
▪ Listen to question carefully, ask for clarification if you are not able to understand.
▪ Get the contextual meaning of the question before you answer.
▪ Answer through the point only
▪ Assume a friendly, cooperative attitude – but do not overdo it
3/27/2017Katalyst HealthCares & Life Sciences
14. 14
Don’t for Audit/ Inspection
▪ Delay in providing requested records or copies of records.
▪ Handover documents to the directly to auditors/ inspectors
▪ Guess, lie, deny the obvious, or make misleading statements.
▪ Walk up to the auditor/ inspector directly to clarify your doubts once the interview/
session is over.
▪ Say that something is impossible or could not happen.
▪ Volunteer information/ Respond to questions that are outside of your area of
expertise or authority
▪ Contradict something being said by a colleague.
▪ Store/ save client documents on your desktop/ personal drive, all documents should
be available in respective Project SharePoint/ Repository
▪ Leave client documents unattended e.g., on your desk, printers, shredders etc.
Keep your desk and surroundings clean and paperless
▪ Leave the auditor unescorted
3/27/2017Katalyst HealthCares & Life Sciences
15. 15
Don’t for Audit/ Inspection
▪ Tailgate to the operations area.
▪ Tell your password even if you are prompted to do so.
▪ Use communicator while presenting your system
▪ Interrupt the auditor without taking permission or being apologetic about the same.
▪ Answer any question without understanding the same.
▪ Indulge in loose talks
▪ Get into a conflicting situations with auditors, if there is a difference of opinion
support this with appropriate reason/ justification
▪ Engage in unconstructive arguments. (also avoid win/ lose or legalistic
confrontations).
▪ Give detailed explanation for closed ended questions
3/27/2017Katalyst HealthCares & Life Sciences
16. 16
Good Documentation Practice (GDP)
▪ Responsibility/ Accountability
▪ Uniformity
▪ Easy flow of information and easiness to understand
▪ Correct information
▪ Exactly matching the requirement/ instruction given
▪ Legibility
▪ Verifiable from original source documents i.e., Audit trail, traceability, supporting
evidences, change log etc
3/27/2017Katalyst HealthCares & Life Sciences
17. 17
Do’s to be followed for GDP
▪ Always sign with date
▪ Use only black or blue ball point pen with permanent ink i.e., indelible ink.
▪ Use consistent date format (global format) i.e., DD-MMM-YYYY, unless
▪ specified by client.
▪ Prefer sign and date instead of initial and date unless specified.
▪ In case of an initial make sure that it is a short sign and not merely first letters of name
and surname.
▪ Use only single diagonal line for correction with new entry along with counter sign and
current date.
▪ Any correction should allow previous entry/ record visible
▪ Write ‘Not Applicable’ or ‘strike off’ as necessary. Put remark why it is not applicable, if
required.
▪ Follow change control process for changes to approved documents.
▪ Carefully review and update change log.
3/27/2017Katalyst HealthCares & Life Sciences
18. 18
Don’ts to be followed for GDP
▪ Back date & future date i.e., Pre/ Post date
▪ Use date stamp & signature stamp
▪ Sign/ date on behalf of others, unless authorised
▪ Delegate signature unless absolute necessity and prior approved
▪ Use pencil, gel/ ink/ pilot/ roller pen, whitener, correction fluid etc
▪ Overwrite/ obliterate/ obscure the original entry.
▪ Perform bulk signatures/ use of flower brackets
▪ Use arrows and dittos.
▪ Use uncommon abbreviations & acronyms.
Be Pro-active …
… rather being Re-active!!
3/27/2017Katalyst HealthCares & Life Sciences
19. 20
Escalation Management: Structured Process
!
An undesirable event occurred in a project or
service that has an impact on Customer.
Escalation
Reported by
Stakeholders (DM/ DD/ AM/ CP/ SBU Head) on
behalf of Customers
Escalation Management Portal is a conducive environment for reporting escalations, in a timely manner to the appropriate levels in
the Organization, and manage them effectively.
Escalation Management as a structured
process helps
identify an undesirable event that
occurred
assess the impact
assign the right stakeholders to
remediate
support appropriate intervention to
manage relationship
communicate, act, learn and prevent
future recurrence… ESCALATION MANAGEMENT
Process & Framework
Impact Assessment &
Allocation
RCA, Action
Planning &
Tracking
Escalation
Resolution
Corrective
and
Preventive
Action
Resolution
Review &
Closure
3/27/2017Katalyst HealthCares & Life Sciences